Webinar: Scientific Imperative of Clinical Trial Diversity & Impact on COVID-19

Most of the currently available data worldwide is showing us that more men are dying of COVID-19, while more women are getting infected. Immunological differences might play a significant role in this, as well as differences in pre-existing conditions. In addition, exposure patterns, testing criteria, case definitions and access to healthcare might modify these patterns.

In this webinar on 9 December from 17:30-19:00 (CET), we’ll explore:

  • The role that genetic variation and gender may play in how a patient responds to a drug or medical product
  • The importance of diversity in clinical trials in general and trials for COVID-19 treatments and vaccinations
  • The status quo in sex and gender-sensitive research and what should be done that is practically feasible in an everyday clinical and research context
  • What the pandemic is teaching us about the impact of sex, gender and ethnicity on health

For those who can’t attend the live session, we’ll provide a recording.

Alekhya Pochiraju will explore how non-Caucasian and underserved populations must be appropriately represented in clinical trials to ensure the efficacy of treatments for all populations. Genetic variation (e.g. ancestral background) may play a key role in how a patient responds to a drug or medical products, yet clinical trials often lack diversity and minority-equity. Having minority populations represented in clinical evaluation ensures robustness and enhances predictability of how new treatments might perform on these demographics.

Professor Dr Sabine Oertelt-Prigione MD, PhD, MScPH, a physician and expert on gender and sex-sensitive research, will give a general overview of the current situation, starting from a medical standpoint and moving into the wider social consequences of this pandemic. She will highlight how the lack of attention to sex and gender can impact statistics, potential therapies and vaccines, livelihoods and the healthcare sector.

Join us for an insightful and interactive conversation.

Agenda

Welcome from Amsterdam and Central - 1 min
Introduction of our speakers - 4 mins
Alekaya's talk - 30 min
Sabine's talk - 30 min
Q&A or breakout interactive - 20 minutes

Learning Objectives

Focus on health equity disparity among people of color

  • The importance of diversity in clinical trials in general and trials for COVID-19 treatments and vaccinations
  • The status quo in sex and gender-sensitive research and what should be done that is practically feasible in an everyday clinical and research context
  • What the pandemic is teaching us about the impact of sex, gender and ethnicity on health

Registration information

Visit the website of HBA to register.

Source: HBA

‹ Events overview